ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novaliq Announces POSITIVE Topline Results for SECOND PHASE 3 TRIAL (ESSENCE-2) of CyclASol® in Dry Eye Disease
December 22, 2021Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial... -
Novaliq Announces More than 50% Patients Enrolled in CyclASol® Phase 3 Dry Eye Disease Trial ESSENCE-2
April 29, 2021Novaliq announced that the second Phase 3 clinical trial evaluating CyclASol® to treat the signs and symptoms of dry eye disease (DED) has randomized more than 50% out of 834 targeted patients, with top-line results expected in the 2nd half of 2021.
Pharma Sources Insight January 2025
